Merck: EXPAND Trial of Erbitux in Advanced Gastric Cancer Does Not Meet Primary Endpoint
05:02 EDT 5 Jul 2012 | LaMerie
- Erbitux in combination with cisplatin and capecitabine does not significantly increase progression-free survival in patients with advanced gastric cancer
- Results do not alter the proven utility of Erbitux in its already approved indications of metastatic colorectal cancer and head and neck cancer
Original Article: Merck: EXPAND Trial of Erbitux in Advanced Gastric Cancer Does Not Meet Primary Endpoint
More From BioPortfolio on "Merck: EXPAND Trial of Erbitux in Advanced Gastric Cancer Does Not Meet Primary Endpoint"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
